Medicenna Short Term Debt vs Other Liab Analysis

MDNA Stock

CAD 1.57 0.08 5.37%

Medicenna Therapeutics financial indicator trend analysis is infinitely more than just investigating Medicenna Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Medicenna Therapeutics is a good investment. Please check the relationship between Medicenna Therapeutics Short Term Debt and its Other Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Short Term Debt vs Other Liab

Short Term Debt vs Other Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Medicenna Therapeutics Short Term Debt account and Other Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Medicenna Therapeutics' Short Term Debt and Other Liab is 0.61. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Other Liab in the same time period over historical financial statements of Medicenna Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Medicenna Therapeutics' Short Term Debt and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Medicenna Therapeutics Corp are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Short Term Debt i.e., Medicenna Therapeutics' Short Term Debt and Other Liab go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Term Debt

Other Liab

Most indicators from Medicenna Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medicenna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 23rd of November 2024, Selling General Administrative is likely to drop to about 4.2 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Interest Income	69K	6.3M	1.2M	1.2M
Net Interest Income	69K	914K	1.2M	1.3M

Interest Income Net Interest Income

Medicenna Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Other Stockholder Equity	Property Plant Equipment	Common Stock Total Equity	Intangible Assets	Other Liab
Total Assets		-0.49	0.15	0.48	0.95	0.91	-0.97	-0.64	0.71	0.97	1.0	-0.02	0.74	0.58	0.37	0.54	1.0	-0.48	0.76	0.35	0.67	0.3	0.61	0.85	-0.81	-0.77
Short Long Term Debt Total	-0.49		-0.18	-0.31	-0.41	-0.51	0.51	0.52	-0.54	-0.49	-0.47	-0.38	-0.51	-0.41	-0.37	-0.05	-0.49	1.0	-0.53	-0.24	-0.32	-0.26	-0.18	-0.59	0.49	0.61
Other Current Liab	0.15	-0.18		0.84	0.05	0.01	-0.23	-0.01	-0.05	0.23	0.15	-0.1	-0.04	-0.14	0.34	0.38	0.15	-0.21	0.0	0.01	0.44	0.16	-0.04	0.03	0.04	0.06
Total Current Liabilities	0.48	-0.31	0.84		0.34	0.37	-0.57	-0.33	0.41	0.57	0.48	-0.04	0.31	0.21	0.55	0.54	0.48	-0.33	0.35	0.02	0.63	0.2	0.03	0.36	-0.36	-0.24
Total Stockholder Equity	0.95	-0.41	0.05	0.34		0.77	-0.88	-0.42	0.58	0.9	0.96	-0.07	0.6	0.53	0.08	0.46	0.95	-0.4	0.56	0.44	0.6	0.1	0.71	0.7	-0.75	-0.69
Net Tangible Assets	0.91	-0.51	0.01	0.37	0.77		-0.9	-0.84	0.76	0.88	0.9	0.06	0.82	0.54	0.63	0.48	0.91	-0.5	0.92	0.25	0.59	0.56	0.5	0.97	-0.77	-0.81
Net Debt	-0.97	0.51	-0.23	-0.57	-0.88	-0.9		0.74	-0.78	-1.0	-0.96	-0.03	-0.82	-0.69	-0.5	-0.56	-0.97	0.51	-0.83	-0.18	-0.61	-0.28	-0.42	-0.88	0.87	0.76
Retained Earnings	-0.64	0.52	-0.01	-0.33	-0.42	-0.84	0.74		-0.82	-0.71	-0.61	-0.35	-0.91	-0.65	-0.82	-0.46	-0.64	0.52	-0.98	0.06	-0.36	-0.53	0.01	-0.92	0.77	0.78
Accounts Payable	0.71	-0.54	-0.05	0.41	0.58	0.76	-0.78	-0.82		0.77	0.68	0.35	0.92	0.76	0.55	0.53	0.71	-0.54	0.83	0.02	0.38	0.19	0.05	0.81	-0.88	-0.81
Cash	0.97	-0.49	0.23	0.57	0.9	0.88	-1.0	-0.71	0.77		0.96	0.01	0.81	0.7	0.46	0.57	0.97	-0.48	0.8	0.18	0.61	0.25	0.43	0.86	-0.87	-0.75
Cash And Short Term Investments	1.0	-0.47	0.15	0.48	0.96	0.9	-0.96	-0.61	0.68	0.96		-0.08	0.71	0.55	0.36	0.53	1.0	-0.46	0.73	0.35	0.67	0.31	0.65	0.83	-0.78	-0.74
Net Receivables	-0.02	-0.38	-0.1	-0.04	-0.07	0.06	-0.03	-0.35	0.35	0.01	-0.08		0.35	0.29	0.16	0.11	-0.02	-0.39	0.26	0.33	-0.05	-0.16	-0.33	0.22	-0.28	-0.51
Common Stock Shares Outstanding	0.74	-0.51	-0.04	0.31	0.6	0.82	-0.82	-0.91	0.92	0.81	0.71	0.35		0.79	0.6	0.54	0.74	-0.51	0.91	0.0	0.33	0.29	0.08	0.88	-0.86	-0.84
Other Current Assets	0.58	-0.41	-0.14	0.21	0.53	0.54	-0.69	-0.65	0.76	0.7	0.55	0.29	0.79		0.29	0.11	0.59	-0.4	0.67	-0.26	-0.04	-0.23	-0.15	0.6	-0.88	-0.53
Total Liab	0.37	-0.37	0.34	0.55	0.08	0.63	-0.5	-0.82	0.55	0.46	0.36	0.16	0.6	0.29		0.38	0.37	-0.38	0.77	-0.19	0.36	0.68	-0.16	0.67	-0.38	-0.42
Short Long Term Debt	0.54	-0.05	0.38	0.54	0.46	0.48	-0.56	-0.46	0.53	0.57	0.53	0.11	0.54	0.11	0.38		0.54	-0.08	0.46	0.3	0.72	0.35	0.22	0.52	-0.44	-0.61
Total Current Assets	1.0	-0.49	0.15	0.48	0.95	0.91	-0.97	-0.64	0.71	0.97	1.0	-0.02	0.74	0.59	0.37	0.54		-0.48	0.76	0.35	0.67	0.3	0.61	0.85	-0.81	-0.77
Short Term Debt	-0.48	1.0	-0.21	-0.33	-0.4	-0.5	0.51	0.52	-0.54	-0.48	-0.46	-0.39	-0.51	-0.4	-0.38	-0.08	-0.48		-0.52	-0.25	-0.34	-0.27	-0.17	-0.58	0.48	0.61
Common Stock	0.76	-0.53	0.0	0.35	0.56	0.92	-0.83	-0.98	0.83	0.8	0.73	0.26	0.91	0.67	0.77	0.46	0.76	-0.52		0.01	0.43	0.52	0.14	0.97	-0.82	-0.81
Property Plant And Equipment Net	0.35	-0.24	0.01	0.02	0.44	0.25	-0.18	0.06	0.02	0.18	0.35	0.33	0.0	-0.26	-0.19	0.3	0.35	-0.25	0.01		0.54	0.13	0.69	0.19	-0.03	-0.49
Non Current Assets Total	0.67	-0.32	0.44	0.63	0.6	0.59	-0.61	-0.36	0.38	0.61	0.67	-0.05	0.33	-0.04	0.36	0.72	0.67	-0.34	0.43	0.54		0.55	0.58	0.56	-0.36	-0.58
Other Stockholder Equity	0.3	-0.26	0.16	0.2	0.1	0.56	-0.28	-0.53	0.19	0.25	0.31	-0.16	0.29	-0.23	0.68	0.35	0.3	-0.27	0.52	0.13	0.55		0.34	0.55	-0.01	-0.35
Property Plant Equipment	0.61	-0.18	-0.04	0.03	0.71	0.5	-0.42	0.01	0.05	0.43	0.65	-0.33	0.08	-0.15	-0.16	0.22	0.61	-0.17	0.14	0.69	0.58	0.34		0.35	-0.12	-0.35
Common Stock Total Equity	0.85	-0.59	0.03	0.36	0.7	0.97	-0.88	-0.92	0.81	0.86	0.83	0.22	0.88	0.6	0.67	0.52	0.85	-0.58	0.97	0.19	0.56	0.55	0.35		-0.82	-0.87
Intangible Assets	-0.81	0.49	0.04	-0.36	-0.75	-0.77	0.87	0.77	-0.88	-0.87	-0.78	-0.28	-0.86	-0.88	-0.38	-0.44	-0.81	0.48	-0.82	-0.03	-0.36	-0.01	-0.12	-0.82		0.78
Other Liab	-0.77	0.61	0.06	-0.24	-0.69	-0.81	0.76	0.78	-0.81	-0.75	-0.74	-0.51	-0.84	-0.53	-0.42	-0.61	-0.77	0.61	-0.81	-0.49	-0.58	-0.35	-0.35	-0.87	0.78

Click cells to compare fundamentals

Medicenna Therapeutics Account Relationship Matchups

Medicenna Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	38.0M	42.3M	23.5M	36.4M	19.1M	19.0M
Other Current Liab	1.3M	1.9K	949K	2.2M	793K	1.2M
Total Current Liabilities	1.8M	4.1M	2.6M	3.8M	2.9M	3.1M
Total Stockholder Equity	36.1M	38.1M	20.8M	29.5M	5.2M	4.9M
Net Tangible Assets	36.1M	38.1M	20.8M	29.4M	33.8M	35.5M
Net Debt	(22.6M)	(30.3M)	(20.5M)	(33.6M)	(17.0M)	(17.8M)
Retained Earnings	(31.1M)	(48.4M)	(70.9M)	(81.0M)	(106.4M)	(101.1M)
Accounts Payable	456.2K	2.2M	1.7M	1.6M	2.1M	1.1M
Cash	22.7M	30.4M	20.5M	33.6M	17.0M	15.0M
Cash And Short Term Investments	37.7M	40.4M	20.5M	33.6M	17.0M	17.5M
Net Receivables	58.3K	410K	1.3M	855K	1.2M	738.2K
Common Stock Shares Outstanding	31.9M	49.7M	54.3M	64.7M	69.6M	38.4M
Liabilities And Stockholders Equity	38.0M	42.3M	23.5M	36.4M	19.1M	19.0M
Other Current Assets	93.8K	1.4M	1.5M	1.9M	931K	742.9K
Total Liab	1.8M	4.1M	2.6M	7.0M	13.9M	14.6M
Total Current Assets	37.9M	42.1M	23.4M	36.4M	19.1M	18.9M
Common Stock	56.6M	79.6M	83.7M	100.9M	116.1M	121.9M
Non Current Assets Total	144.0K	103K	65K	61K	57.0K	87.7K
Other Stockholder Equity	10.4M	(31.2K)	(12.7K)	(19.9K)	10.7M	11.2M
Accumulated Other Comprehensive Income	248.5K	234K	171K	57K	19K	18.1K
Intangible Assets	76.3K	71.0	65.0	61.0	57K	43.9K
Non Currrent Assets Other	81.2K	144.0K	(103.0)	(1.0)	(0.9)	(0.85)
Non Current Liabilities Total	32.0K	0.0	1.7M	3.2M	11.1M	11.6M
Capital Surpluse	10.4M	6.7M	7.9M	9.5M	10.9M	7.7M
Cash And Equivalents	22.7M	30.4M	20.5M	33.6M	38.6M	20.0M
Net Invested Capital	36.1M	38.1M	20.8M	29.5M	5.2M	4.9M
Net Working Capital	36.0M	38.0M	20.8M	32.6M	16.2M	23.4M
Capital Stock	56.6M	79.6M	83.7M	100.9M	116.1M	80.4M

Pair Trading with Medicenna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Medicenna Stock

0.64	TSLA	Tesla Inc CDR	Pair Corr
0.48	WMT	Walmart Inc CDR	Pair Corr
0.41	AMZN	Amazon CDR	Pair Corr
0.32	TD-PFI	Toronto Dominion Bank	Pair Corr

The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.

The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medicenna Stock

Balance Sheet is a snapshot of the financial position of Medicenna Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Medicenna Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Medicenna Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Medicenna currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Medicenna Short Term Debt vs Other Liab Analysis

Short Term Debt vs Other Liab

Short Term Debt vs Other Liab Correlation Analysis

Correlation Coefficient

Short Term Debt

Other Liab

Medicenna Therapeutics fundamental ratios Correlations

Medicenna Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medicenna Therapeutics fundamental ratios Accounts

Pair Trading with Medicenna Therapeutics

Moving against Medicenna Stock

Other Information on Investing in Medicenna Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Short Term Debt	+ 1.0	Short Long Term Debt Total
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.97	Total Assets
Common Stock Total Equity	+ 0.97	Net Tangible Assets

Cash	- 1.0	Net Debt
Common Stock	- 0.98	Retained Earnings
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.97	Total Assets
Cash And Short Term Investments	- 0.96	Net Debt
Common Stock Total Equity	- 0.92	Retained Earnings